Although the direct oral anticoagulants (DOACs) do not require routine monitoring and
reduce bleeding compared with warfarin, there are special circumstances in which …

Direct oral anticoagulants (DOACs) have at least noninferior efficacy compared with other
oral anticoagulants and have ancillary benefits, including overall better safety profiles, lack …

Although the direct oral anticoagulants (DOAC s) do not require routine laboratory
monitoring, there may be special situations in which measurement of drug levels is …

Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in
the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban …

Bleeding is the main complication of oral anticoagulant (OAC) therapy, with major bleeds
occurring in about 2% to 4% of OAC-treated patients per year. Although direct oral …

Background Direct oral anticoagulants (DOACs) are the treatment of choice for most patients
with atrial fibrillation and/or noncancer-associated venous thromboembolic disease …

The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban,
apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous …

Direct oral anticoagulants (DOACs) are increasingly used for prevention and treatment of
venous thromboembolism and for prevention of stroke in patients with nonvalvular atrial …

The first direct oral anticoagulant (DOAC) to be approved for clinical use was dabigatran, a
direct thrombin inhibitor, in 2010. Since that time, four additional DOACs, all direct anti‐Xa …

Thrombin inhibitor dabigatran and factor Xa inhibitors rivaroxaban, apixaban and edoxaban
form a new class of non-vitamin K antagonist oral anticoagulants and have been extensively …